Aug. 4 at 10:23 PM
$LUCD The Castle Biosciences report today MIGHT let some reality enter into the PUMPERS.
Castle completed the purchased of Capsulomics in Q2 2025, trading as Previse and as there is NO MENTION of how much it cost it can NOT have been material. So probably less than
$1M, certainly less than
$5M.
Castle is PROFITABLE, with a GROSS MARGIN of around 80%. EsoGuard is 90%.
Castle had cash of
$275MILLION, and NET Income of
$4.5M. They make money unliked LUCD which loses
$50M+ per year. CSTL's Market Cap is
$450M which when you back out cash of
$275M is
$175M.
As Castles Annual Revenue is around
$350M that means Wall Street is valuing a PROFITABLE diagnostic company in LUCD's space at about 50% of Annual revenue after subtracting cash on hand.
This is why Lishan and Dennis will DILUTE DILUTE DILUTE. Wall Street will not give them a valuation much different than Castle. With
$5M in Revenue and out of cash in December that is a valuation of about
$2.5M.
EXAS will buy for about
$2 to
$2.5
